JAIDS Journal of Acquired Immune Deficiency Syndromes
29:549–552 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 29, 2002

Author Index

Aarnoutse RE, 101
Abrams DI, 221
Aceti A, 41
Acosta EP, S11
Adorni F, 21
Agarwal B, 181
Agut H, 204
Aidoo S, 511
AIDS Clinical Trials Group 334 Investigators, 356
AIDS Vaccine Evaluation Group, 254
Aiuti F, 122
Al-Harthi L, 544
Alvord WG, 330
Anastos K, 495
Anderson JE, 104
Andréoletti L, 102
Andreoni M, 295
Angelini C, 300
Antiochos BB, 323
Arduino RC, 317
Arendt G, 363
Arnsten JH, 69
Arpadi SM, 450
Autran B, 204
Avila MM, 422

Bangsberg D, 504
Baratin D, 319
Barceló JJ, 429
Bartholow BN, 76
Bartlett JA, S2
Baruchel S, 158
Basso S, 374
Bastos FI, 95
Baum M, 169
Beardsell A, 547
Bebchuk JD, 221
Beijnen JH, 464
Bekoe V, 402
Bélec L, 102, 203
Ben K, 191
Berrey MM, 232
Beyrer C, 62
Bhatia K, 181
Bickel M, 117
Biggar RJ, 418
Bischofberger N, 207
Blattner W, 484
Boakye D, 511
Bogard E, 132
Bohlin A-B, 396
Bonard D, 149
Bondurand A, 149
Bonifati D, 300
Bonjoch A, 244
Boonrod C, 455
Borroto-Esoda K, 11
Botet FA, 396
Braitstein P, 547
Bratt G, 441
Brewer TH, 289
Brizendine E, 49
Brown A, 330
Buchbinder SP, 307
Burbano X, 169
Burger DM, 101
Busch MP, 478
Butel JS, 109
Byers RH Jr, 378
Bylund H, 441

Cahn P, 368
Cahour A, 204
Calabrese LH, 356
Calamy G, 102
Camp A, 49
Candotti D, 204
Cardiello PG, 464
Carmona R, 536
Carolo G, 295
Carpenter LM, 174
Carr JK, 422
Carrillo MG, 422
Carrington M, 307
Carrion G, 422
Cartoux M, 517
Casseb J, 435
Cassel-Beraud A-M, 427
Castelli F, 315
Castillo A, 207
Castillo G, 169
Cauda R, 546
Celentano DD, 62, 76
Celum C, 307
Chaikummao S, 284
Chaisson RE, 546
Chan K, 547
Chang LW, 511
Charurat M, 484
Chernoff D, 330
Chevalier P, 427
Chidiac C, 319
Chohan V, 262
Choopanya K, 86
Chu PL, 504
Chuenyam T, 455
Cingolani A, 546
Claeys P, 262
Clavel F, 102
Clotet B, 244
Combe P, 149
Concia E, 295
Conti S, 105
Coombs RW, 356
Cooper DA, 455, 464
Cooper ER, 484
Corey L, 232, 254
Corsico L, 21
Coulibaly I, 149
Crialesi R, 105
Cruceta A, 429
Cuevas L, 536
Cuevas MT, 536
Cuff PA, 450
Curran JW, 511

d'Arminio Monforte A, 21
Dabis F, 149
Dai J, 191
Dale M, 478
Davey RT, 221
De Bac C, 41
De Cristofaro MR, 122
De Luca A, 546
De Simone N, 300
de Souza CTV, 95
de Souza M, 330
Dean M, 307
Defer MC, 517
Delaporte E, 165, 522
Delgado E, 536
Denning ET, 221

Des Jarlais DC, 86
Detels R, 346
Dewar R, 330
Di Giambenedetto S, 546
Diagbouga S, 427
Diaz C, 484
Diaz T, 95
Diem K, 232
Dieterich DT, 340
Diz-Aren J, 536
Dolin R, 254
Dondero D, 307
Dore GJ, 388
Duerr A, 275
Durand A, 374
Dworkin MS, 378
Dzokoto A, 402

Eiumtrakul S, 62
Ekert JE, 207
Ekra D, 149
Elbeik T, 330
Enge B, 531
Engels EA, 418
Ensoli F, 122
Esparza J, 184
Essex M, 409
Estrada V, 32
Evans TG, 254

Fabry J, 319
Farchi F, 295
Fawzi W, 409
Federico A, 368
Fernández C, 32
Fernandez JJ, 323
Ferrazin A, 396
Ferrer M^{a}J, 244
Fisher M, 58
Ford W, 76
Forney D, 54
Fox L, 221, 356
French AL, 495
Frey SE, 254
Fridlund C, 478
Frova L, 105
Fumaz CR, 244

Gaillard P, 262
Galai N, 62
Gallais H, 374
Gallart T, 429
Galli M, 21
Gambotti L, 319
Gange SJ, 495
García A, 429
García F, 429
Gardner LI, 69
Gastaut J-A, 374
Gatell JM, 429
Gerken G, 145
Gervasoni C, 21
Gianelli E, 21
Giannini F, 300
Giaquinto C, 396
Gillini LA, 546
Giorgi JV, 346
Giovannetti A, 122
Goedert JJ, 418
Goepfert P, 254
Goldberg J, 49
Gomez IdJ, 396
Gopal R, 181
Gorse GJ, 254
Gourvellec G, 149
Gouws E, 531
Graham B, 254
Gray-Donald K, 158
Greenblatt RM, 495
Grésenguet G, 203
Guevara H, 435
Gupta K, 254
Gwinn M, 478

Hadley K, 330
Hageman CA, 1
Hagy A, 511
Halvorson SJ, 109
Han X, 317
Handelsman E, 484
Hanson CV, 435
Hanson IC, 484
Harris JL, 11
Harro C, 254
Hassink EA, 464
Hassink EAM, 455
Hauck WW, 270
Hayani K, 484
Hekster YA, 101
Hendry RM, 435
Hertogs K, 522
Heyward WL, 86
Hierholzer J, 422
Hireanras K, 86
Hoetelmans RM, 464
Hoetelmans RMW, 455
Hoff R, 484
Hogg RS, 547
Holmberg SD, 69
Hooper BJ, 11
Hoover EA, 1
Horlick M, 450
Hsu L, 504
Hudgens M, 254
Huët C, 149
Hugen PWH, 101
Hultin LE, 346
Hurley L, 504
Hutman HW, 471
Huygens P, 517

Inion I, 262

Jamieson BD, 346
Janssen RS, 76, 478
Jesudason MV, 320
Johnson MA, 58, 197
Johnson R, 356
Jou T, 244

Kaitoo EE, 402
Kaldor JM, 388
Kamali A, 174
Kannangai R, 320
Kapiga SH, 409
Karim SA, 531
Katz M, 504
Katzenstein DA, 435
Kawichai S, 62, 275
Kazatchkine MD, 102
Keefer MC, 254
Keiser P, S19
Kengeya-Kayondo JF, 174
Ketelsen U-P, 117
Khamboonruang C, 62
Khonde N, 402
Kijak G, 368
Kilmarx PH, 284
Kingkeow D, 275
Kinsman J, 174
Kintu P, 174
Kirstein LM, 495
Kitayaporn D, 86
Kiwelu IE, 409
Kiwuuwa S, 174
Koblin BA, 76
Köller H, 363
Koo BCA, 340
Koopmans PP, 101
Koppel K, 441
Kothe D, 478
Kotler DP, 450
Kozinetz CA, 109
Kubow S, 158
Kuntz KM, 132

Lacarelle B, 374
Laine C, 270
Lalonde RG, 158
LaLota M, 76
Lampe F, 58
Lamson M, 471
Landay A, 544
Lane HC, 221
Lange JM, 464
Lange JMA, 455
Larrad MTM, 32
Lecusay R, 169
Lederman MM, 356
Lednicky JA, 109
Lejeune M, 429
Leti W, 122
Levine A, 495
Li Y, 388
Limpakarnjanarat K, 284

Limpongsanurak S, 455
Linley L, 478
Liu H, 191, 314
Lokeshwas N, 181
López AG, 32
Losada E, 536
Louisirirotchanakul S, 314
Loveday C, 58
Luo J, 191
Lyles RH, 346

MacKellar DA, 76
Mahanontharit A, 464
Maleno MJ, 429
Malkin J-E, 102
Malonga-Mouellet G, 165
Manca N, 300
Mandaliya K, 262
Manongi R, 409
Manopaiboon C, 284
Mansaray H, 165
Margolick JB, 346
Marimoutou C, 149
Marinello M, 422
Markowitz NP, 221
Marsh K, 504
Marshak A, 471
Martin RB, 207
Martínez C, 429
Marziali M, 122
Masenga EJ, 409
Masocco M, 105
Mastro TD, 86, 284
Matta M, 102
Matud JL, 346
Maulen S, 422
Mavoungou R, 165
Mayaud P, 203
Mayer KH, 69
Mazzetta F, 122
Mazzi R, 295
Mbizvo M, 435
Mbopi-Kéou F-X, 102, 203
Mboup S, 522
Mbulaiteye SM, 418
McCreedy B, 11
McDermid JM, 158
McDonald A, 388
McDonough M, 471
McElrath MJ, 254
McFarland W, 76
McLeod A, 547
Meda N, 517
Medrano L, 536
Mei J, 478
Mellors JW, 346
Metsch LR, 289
Mewshaw JP, 11
Meyer zum Büschenfelde K-H, 145
Michael NL, 307, 330
Miguez M-J, 169
Mildvan D, 356, 471
Minga A, 149
Minkoff H, 495
Miralles C, 536
Miró JM, 429
Mistoul I, 165
Mocherla S, 49
Mock PA, 86, 284
Mocroft A, 58
Mofenson L, 484
Mok JYQ, 396
Mondor M, 402
Montagnier L, 149
Montaner JSG, 368, 547
Montavon C, 522
Montefiori DC, 254
Moore AL, 197
Moore J, 69
Moore RD, 54
Moroni M, 21
Mulligan M, 254
Mur A, 396
Murri R, 546
Mwanyumba F, 262
Myrick FT, 11

Nagot N, 517
Nair R, 181
Nájera R, 536
Nakayama EE, 314
Nakiyingi J, 174
Nalweyiso N, 174
Nannini EC, 317
Naresh KN, 181
Nassos P, 330
Negredo E, 244
Negrete M, 422
Nelson KE, 62, 275
Nerrienet E, 149
Newell M-L, 396
Ng VL, 330
Nicastri E, 295
Nkengasong JN, 522

O'Brien S, 307
O'Brien SJ, 1
O'Brien WA, 317
O'Shaughnessy MV, 547
Ocampo A, 536
Ochoa C, 368
Ojea-de Castro R, 536
Olivero OA, 323
Opare B, 402
Osei-Kwasi M, 511
Osmanov S, 184
Ouangré A, 517
Ouedraogo A, 517

Palmon R, 340
Pando MA, 422
Pappagallo M, 295
Paredes R, 244
Parekh B, 478
Parekh N, 356
Parisi MK, 504
Parisi SG, 295
Pasquazzi C, 41
Patroni A, 315
Pattou C, 184
Paul J-L, 203
Payne M, 174
Pearlman J, 504
Peeters M, 165, 522
Peltier A, 396
Peng Z, 191
Pépin J, 402
Peralta LM, 422
Perandin F, 300
Perdue TE, 76
Perez H, 368
Pérez-Álvarez L, 536
Peyramond D, 319
Pezzotti P, 105
Phair JP, 346
Phanuphak P, 455, 464
Phillips AN, 58, 197
Piazza M, 21
Pierdominici M, 122
Piketty C, 102
Pineda L, 169
Pitt J, 484
Plana M, 429
Poirier MC, 323
Poizot-Martin I, 374
Powderly WG, S28
Prabu K, 320
Praet M, 262
Prazuck T, 102
Pu D, 191
Pumarola T, 429
Puoti M, 315

Qin S, 191
Quigley MA, 174
Quiros-Roldan E, 315

Radecke K, 145
Raktham S, 86
Ramalingam S, 320
Ramanathan U, 181
Ransom D, 58
Ravasio L, 21
Ravaux I, 374
Rawal BD, 478
Ree H, 388
Renjifo B, 409
Rezza G, 105, 295
Rickerts V, 117
Ridolfo AL, 21
Rinaldo CR Jr, 346
Robinson P, 471
Robison V, 275
Rodriguez A, 169
Rodríguez-Pérez R, 536
Romeu J, 244

Rompalo A, 69
Rongkavilit C, 455
Roongpisuthipong A, 314
Roubache J-F, 203
Royalty J, 478
Ruiz P, 169
Russell KL, 422
Ruxrungtham K, 455, 464

Sabin CA, 197
Salamon R, 149
Salomon H, 368, 422
Sam NE, 409
Samor TM, 464
Sampson J, 221
Sanchez J, 422
Sandström E, 441
Santini-Muratori D, 122
Sarmati L, 295
Satten GA, 478
Sauvé N, 402
Schlaak JF, 145
Schnizlein-Bick C, 49
Schock B, 356
Schöfer H, 117
Schramm C, 145
Schulman S, 441
Schuman P, 69
Schwarcz S, 504
Schwardländer B, 184
Schwartz DH, 254
Secura GM, 76
Selik RM, 378
Semba RD, 142
Sennum S, 275
Serrano-Ríos M, 32
Setzer B, 117
Shah N, 142
Shao JF, 409
Shea T, 232
Shehan D, 76
Sheppard HW, 307, 531
Shioda T, 314
Shor-Posner G, 169
Shoultz DA, 340
Siebers MC, 101
Sierra M, 536
Silver S, 495
Si-Mohamed A, 102
Sirera G, 244
Sleiman I, 315
Smeriglio V, 484
Smith DK, 69
Smith KY, 544
Solas C, 374
Spearman PW, 254
Spritzler J, 356
Srasuebkul P, 464
Sridharan G, 320
Srigritsanapol A, 455
St Claire ME, 323
Stall R, 104
Staszewski S, 117
Steffens CM, 544
Story A, 58
Strathdee SA, 142
Sujarita S, 86
Supawitkul S, 284
Suriyanon V, 275
Sutmoller F, 95

Taboada JA, 536
Takebe Y, 191, 314
Tanan P, 275
Tarantal AF, 207
Téllez MJ, 32
Temmerman M, 262
Thaithumyanon P, 455
The LIVERHAART Group, 41
Theisen A, 363
Thibault V, 204
Thomson MM, 536
Thorne C, 396
Thornton J, 450
Tinelli C, 315
Toccaceli V, 105
Torian LV, 76
Torti C, 315
Touraine J-L, 319
Toure-Kane C, 522
Tovanabutra S, 275
Traore Y, 427
Trépo C, 319
Trichavaroj R, 330
Truckenbrod A, 544
Truong H-HM, 232
Tuldrà A, 244
Tural C, 244
Turner BJ, 270
Tyrer M, 58

Ubolyam S, 455

Vaccarezza M, 21
Vail GM, 49
Valleroy LA, 76
Van de Perre P, 427, 517
van Heeswijk RP, 464
van Heeswijk RPG, 455
VandeWoude S, 1
Vanhems P, 319
Vanichseni S, 86
Vansteelandt S, 262
Vázquez-de Parga E, 536
Venhoff N, 117
Vergne L, 165, 522
Verheggen R, 221
Verhofstede C, 262
Vermund SH, 511
Vichi M, 105
Vidal C, 429
Vilchez RA, 109
Villahermosa ML, 536
Villar NGP, 32
Vlahov D, 142
Volberding PA, S1
Volksbeck SIL, 117
von Giesen HJ, 363

Wagner JL, 323
Wakefield DACS, 11
Walker N, 184
Walker UA, 117
Wang J, 450
Wasi C, 314
Wei T, 191
Weinhold K, 254
Weinstock H, 478
Weiss L, 102
Wheat LJ, 49
White ZS, 109
Whitworth JAG, 174
WHO-UNAIDS Network for HIV Isolation and Characterization, 184
Williams BG, 531
Wilson D, 58
Wongtrakul J, 275
Worarien W, 464
Wu A, 546

Xia X, 191
Xu F, 284

Yamashita TE, 346
Yang R, 191
Yanpaisarn S, 284
Yarrish R, 471
Yen-Lieberman B, 356
Youle M, 58
Young NL, 284

Zala C, 368
Zechini B, 41
Zeh D, 221
Zékiba T, 517
Zenilman JM, 289
Zhang C, 191
Zhang D, 270
Zhang Z, 191
Zijenah LS, 435

JAIDS Journal of Acquired Immune Deficiency Syndromes
29:553–561 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 29, 2002

Subject Index

Acute retroviral syndrome, concordance of HIV source partner identification and molecular confirmation in, 232
Adherence
  challenges of, S2
  in HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens, 232
Adipose tissue
  maldistribution of in HIV-infected men treated with antiretroviral therapy, 32
  nucleoside analog reverse transcriptase inhibitor-associated mitochondrial defects in, 117
Adolescents, vertically acquired HIV infection in, 396
Africa
  high incidence of HIV-1 in, 531
  HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in, 511
  HIV exposure risk among commercial sex workers in, 517
  HIV infection in a semiurban community of, 402
  independent effects of sexually transmitted disease and sexual behavior on HIV-1 prevalence in, 174
  natural history of HIV-1 infection in, 149
  new circulating recombinant form of HIV-1 subtypes in, 522
  resistance to antiretroviral treatment in, 165
  thymic size and muscle mass in asymptomatic HIV-infected children in (letter), 427
  vitamin A deficiency and genital tract infections among women in (letter), 203
AIDS, prevalence of iron deficiency and anemia among female injection drug users with, 142
AIDS dementia, impact of HAART on, 388
AIDS progression, immunologic and virologic markers predicting, 346
AIDS-related illness
  impact of HAART on, 388
  in the United States, 418
AIDS-related systemic non-Hodgkin lymphoma, detection of SV40 tumor antigen in, 109
AIDS Vaccine Evaluation Group Protocol 022A, for evaluation of safety and immunogenicity, 254
Amplicor, HIV-1 monitor version 1.5, 330
Anal sex, unprotected, socioeconomic status and crack/cocaine use and among gay and bisexual men, 95
Anemia
  in HIV-infected patients receiving highly active antiretroviral therapy, 54
  prevalence of in female injection drug users, 142
Animal models, in FIV superinfection resistance, 1
Antioxidants, oxidative stress and in HIV infection, 158
Antiretroviral therapy. *See also* Highly active antiretroviral therapy; Protease inhibitors
  adherence to, S2
  anemia with, 54
  body habitus and metabolic changes with, 21
  CNS effects of, 363
  combination
    for pregnant HIV-1-infected women, 484
    prophylactic, safety and tolerability of (letter), 547
  complexity of regimens in, S2
  cyclosporin-A in, 356
  for drug-resistant HIV-1 isolates, 11
  hepatotoxicity development during, 41
  HIV-1 RNA viral load monitoring in drug users on, 270
  in HIV-infected women, 69
  impact of on AIDS-defining illness incidence and survival in Australia, 388
  implementing guidelines for use of, 165
  leptin and adipose tissue maldistribution with, 32
  long-term, navigating emerging challenges to, S1
  long-term toxic effects of, S28
  multidrug, two-year outcome of, 58
  nucleoside analog, in *Erythrocebus patas* monkeys, 323
  protease inhibitor-based and -sparing (letter), 544
  resistance to in Gabon, 165
  sequencing in selection of, S19
  variability in over time, 495
Argentina, HIV-1 epidemics in, 422
Asia, simplifying protease inhibitor therapy in, 464
At-risk populations, need for behavioral surveys of (letter), 104
Australia, impact of HAART on AIDS-defining illness incidence and survival in, 388

Bangkok, incarceration and HIV risk among injection drug users in, 86
Bar workers, HIV-1 epidemic among in Tanzania, 409
Bayer Versant HIV-1 RNA 3.0, versus Roche Amplicor HIV-1 Monitor Version 1.5, 330
Behavioral surveys, for at-risk populations in United States (letter), 104
β-Chemokine production, changes in with HAART, 122
BG recombinant HIV subtype, identification of, 536
Bisexual men
  repeat HIV testing among, 76

socioeconomic status and crack/cocaine use with unprotected anal sex and among, 95
Body habitus, changes of in protease inhibitor-naive HIV-1-infected patients treated with nucleoside reverse transcriptase inhibitors, 21
Bone biomarkers, after tenofovir administration in gravid Rhesus monkeys, 207
Bone disease, with long-term therapy, S28
Bone mineral content, in prepubertal HIV-infected children, 450
Branched DNA, HIV-1 viral load assays of, 330
Brazil, socioeconomic status and crack/cocaine use with unprotected anal sex in gay and bisexual men in, 95
Burkina Faso, HIV exposure risk among commercial sex workers in, 517

Canarypox vaccines, safety and immunogenicity of, 254
Cancers, with HIV infection from 1987–1999, 378
CCR5-Δ32/Δ32 genotype, HIV-1 infection with, 307
CCR5 expression, changes in with HAART, 122
CCR2 64I homozygosity, HIV-1-negative status and (letter), 314
CCR5 receptors, in HIV-1 infection, 307
CD38, in HIV-1 infection prognosis, 346
CD4 cell counts
in HIV-1 infection prognosis, 346
with interleukin-2 for HIV/hepatitis C virus coinfection, 145
with recombinant interleukin-2, 221
Cellular immune response, in HIV-infected patients with histoplasmosis, 49
Central nervous system
disorders of, in HIV-1-infected patients treated with efavirenz versus protease inhibitors-containing regimens, 232
therapeutic effects of nonnucleoside reverse transcriptase inhibitors on, 363
Chemokine receptors, changes in β-chemokine expression at with HAART, 122
Children
lower bone mineral content in, 450
thymic size and muscle mass with asymptomatic HIV infection in (letter), 427
with vertically acquired HIV infection, 396
China, HIV-1/hepatitis C virus coinfection among injection drugs users in, 191
Chronic disease, iron deficiency and anemia among female injection drug users with, 142
Circulating recombinant forms
global distribution and regional spread of, 184
identification of, 536
Clinic-based counseling, HIV-1 incidence and, 284
Cocaine use, socioeconomic status and in gay and bisexual men, 95
Cohort study
of gender and clinical outcomes after HAART, 917
of preventive behaviors counseling among married women and HIV-1 incidence in northern Thailand, 284
Combination antiretroviral therapy
for pregnant HIV-1-infected women and perinatal transmission, 484
prophylactic, safety and tolerability of (letter), 547
Commercial sex
and HIV infection in young men in Thailand, 62
spectrum of in Burkina Faso, 517
Compliance, to antiretroviral regimen, S2
Condom use, HIV-1 incidence and in northern Thailand, 284
Coreceptors, in HIV-1 infection, 307
Counseling, of married women, HIV-1 incidence and in northern Thailand, 284
Crack use, socioeconomic status and in gay and bisexual men, 95
CRF06-cpx, in West Africa, 522
CXCR4 receptors
changes in expression with HAART, 122
in HIV-1 infection, 307
Cyclosporin-A, placebo-controlled trial of in HIV-1 disease, 356
Cytochrome P-450 enzymes, in protease inhibitor pharmacokinetics, S11
Cytotoxic dose, 50%, in inhibition of drug-resistant HIV-1 isolates, 11

Death certificates, mentioning HIV infection, 378
Developing countries, guidelines for antiretroviral therapy use and monitoring of HIV-1 drug resistance in, 165
Diaminopurine dioxolane, inhibiting drug-resistant HIV-1 infection, 11
Didanosine, hydroxyurea added to stavudine plus nevirapine and, 368
Diet, antioxidants in and oxidative stress in HIV infection, 158
Dioxolane guanosine, inhibiting drug-resistant HIV-1 infection, 11
Dipeptide insertions, multidrug-resistant HIV-1 RNA and proviral DNA variants harboring (letter), 102
Discontinuation, of HAART regimen, 495
Disease progression
gender and after HAART, 917
of HIV-1 seroconverters in Ivory Coast, 149
Disease reporting, non-name-based systems, 504
Disease stage, immunologic and virologic markers predicting, 346
DNA sequencing, HIV source partner identification and, 232
Dose
adjusting for toxicity, indinavir, 374
viral load and, 221
Dose-escalating study, of nelfinavir in HIV-exposed neonates, 455
Drug experienced patients, two-year outcome with multidrug regimen in, 58
Drug interactions
with long-term HIV therapy, S1
of nevirapine and ethinyl estradiol/norethindrone, 471
of saquinavir soft-gelatin capsules/ritonavir, 464
Drug resistance
among HIV-1-infected patients in Gabon, 165
antiretroviral sequencing and, S19
declining rates of among HIV-positive patients in Italian teaching hospital (letter), 546
genotypic HIV-1, testing of (letter), 317
with long-term HIV therapy, S1

Drug-resistant HIV-1 isolates, dioxolane guanosine as potent inhibitor of, 11
Drug side effects, in adherence to antiretroviral regimen, S2

Efavirenz
CNS effects of, 363
quality of life, emotional status, and adherence to regimen with, 232
sequencing of, S19
Effective concentration, 50%, in inhibition of drug-resistant HIV-1 isolates, 11
Electron microscopy, for genetic and structural defects of adipose tissue mitochondria associated with reverse transcriptase inhibitors, 117
Emotional status, in HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens, 232
Envelope antibody, in HIV-1 subtype C virus, 435
Enzyme-linked immunosorbent assay (ELISA), sensitive/less-sensitive, in HIV-1 prevalence survey, 531
Epidemiology
of HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients, 511
of HIV-1 genetic subtypes, 184
of HIV-1 in Argentina, 422
molecular, 232
U.S. death certificates mentioning HIV infection and, 378
of vertically acquired HIV in older children and adolescents, 396
Epstein-Barr virus, in HIV-positive individuals in India, 181
Erythrocebus patas monkeys, antiretroviral nucleoside analog therapy in, 323
Ethinyl estradiol/norethindrone, pharmacokinetic interactions with nevirapine, 471
Europe, vertically acquired HIV in older children and adolescents in, 396

Fat loss, with antiretroviral therapy, 32
Fatigue, with HAART, 54
Feline immunodeficiency virus, lion and puma lentiviruses in resistance to superinfection by, 1
Fetal outcome, after tenofovir administration, 207
Fetus/telomere, antiretroviral nucleoside analog therapy in, 323
Fibrinogen, with protease inhibitor-containing HAART, 441
Fibrinolysis, impaired, with protease inhibitor-containing HAART, 441

Gabon, resistance to antiretroviral treatment in, 165
Gay men
HIV seroincidence of with sexually transmitted disease, 478
repeat HIV testing among, 76
socioeconomic status and crack/cocaine use with unprotected anal sex and among, 95
Gender
clinical outcome and after HAART, 917
pharmacokinetic variability and with indinavir exposure (letter), 101
Genetic analysis, of HIV-1 discordant couples in Thailand (letter), 314
Genetic sequences, in myasthenia gravis, 300
Genetic subtypes, with different risk groups, 422
Genital tract infections, vitamin A deficiency and in African women (letter), 203
Genotypic HIV-1 drug resistance testing, in antiretroviral-naive subjects in Houston, Texas (letter), 317
Geographic distribution, of HIV-1 subtypes, 184
Ghana
HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in, 511
HIV infection in a semiurban community of, 402
Glutathione, oxidative stress and in HIV infection, 158

Health care, time between first detection of HIV antibodies and first contact for (letter), 319
Hemoglobin
in female injection drug users, 142
with HAART, 54
Hepatitis B virus, in hepatotoxicity development during antiretroviral therapy, 41
Hepatitis C virus
coinfection of among HIV-1-infected injection drug users in China, 191
coinfection of and lipid abnormalities in HIV-positive patients on HAART (letter), 315
in hepatotoxicity development during antiretroviral therapy, 41
iron deficiency and anemia among female injection drug users with, 142
in long-term nonprogressor HIV-1-infected subjects (letter), 204
sustained suppression of replication and inflammatory activity of after interleukin-2 therapy, 145
Hepatitis virus, prevalence of in HIV-infected patients, 295
Hepatotoxicity
during antiretroviral therapy containing protease inhibitors, 41
lack of with nonnucleoside reverse transcriptase inhibitors, 340
Herpesvirus, Kaposi sarcoma-associated, in people with AIDS in the United States, 418
Heteroduplex mobility assay, HIV source partner identification and, 232
Heterosexual transmission
clinic-based counseling on preventive behaviors among married women and, 284
of HIV in STD clinic patients, 478
male viral load for HIV-1 subtype E and, 275
High-titered canarypox vaccines, combined with rgp120, safety and immunogenicity of, 254
Highly active antiretroviral therapy (HAART)
anemia with, 54
CCR5 and CXCR4 expression and β-chemokine production changes with, 122
combination, for pregnant HIV-1-infected women, 484
declining tuberculosis and drug resistance rates with (letter), 546
gender and clinical outcomes after, 917

hepatitis C virus coinfection and lipid abnormalities with (letter), 315
in HIV-infected women, 69
hypofibrinolytic state with, 441
immune reconstitution after, 429
impact of on AIDS-defining illness incidence and survival in Australia, 388
long-term toxic effects of, S28
during pregnancy, 207
selenium status and mycobacterial disease among drug users on, 169
sequencing options in, S19
toxicity of, 374
variability in over time, 495
in vertically acquired HIV in older children and adolescents, 396
Histoplasmosis, cellular immune response with, 49
HIV-1 antibody, in subtype C virus infection, 435
HIV-1 BG intersubtype circulating recombinant form, identification of, 536
HIV-1 discordant couples, genetic analysis of (letter), 314
HIV-1 drug resistance, guidelines for monitoring of, 165
HIV-1 epidemics
among female bar and hotel workers in northern Tanzania, 409
in Argentina, 422
HIV-1 incidence
clinic-based counseling and, 284
global, in year 2000, 184
in South Africa, 531
HIV-1 infection
body habitus and metabolic changes with nucleoside reverse transcriptase inhibitors in, 21
with CCR5-Δ32/Δ32 genotype, 307
HIV-1 isolates, drug-resistant, dioxolane guanosine as potent inhibitor of, 11
HIV-1 prevalence
among injection drug users in China, 191
independent effects of sexually transmitted disease and sexual behavior on in rural Uganda, 174
HIV-1 RNA viral load monitoring, in HIV-infected drug users on antiretroviral therapy, 270
HIV-1 seroconverters, clinical biological evolution of in Ivory Coast, 149
HIV-1 subtype C
high incidence of in South Africa, 531
maternal HIV-1 antibody and vertical transmission in, 435
HIV-1 subtype E, male viral load and heterosexual transmission of in northern Thailand, 275
HIV-1 subtypes
comparative analysis of viral load assays on, 330
global distribution and regional spread of in year 2000, 184
new circulating recombinant form of, 522
HIV-1 viral load assays, comparative analysis of on subtype quantification, 330
HIV antibodies, first detection of and first contact for healthcare (letter), 319
HIV-exposed neonates, dose-escalating study of safety and pharmacokinetics of nelfinavir in, 455
HIV exposure, with commercial sex activity, 517
HIV G subtype, identification of, 536
HIV/hepatitis C virus coinfection, sustained suppression of HCV replication and inflammatory activity of after interleukin-2 therapy, 145
HIV incidence, self-reported sexual risk behavior and, 289
HIV-infected men, leptin and adipose tissue maldistribution with antiretroviral therapy in, 32
HIV infection
excess mortality from non-AIDS-related diseases with (letter), 105
lipodystrophy with reverse transcriptase inhibitors for, 117
HIV reporting system, non-name-based, 504
HIV RNA load
in HIV-1 infection prognosis, 346
with recombinant interleukin-2, 221
HIV seroconversion
among young gay and bisexual men, 76
standardized algorithm for, 531
time between first detection of HIV antibodies and first contact for health care in (letter), 319
HIV seroincidence, in sexually transmitted disease clinic patients, 478
HIV source partner identification, molecular confirmation and in acute retroviral syndrome, 232
HIV specialist care, for HIV-infected women, 69
HIV testing, repeat, among young gay and bisexual men, 76
HIV transmission
among incarcerated injection drug users in Thailand, 86
perinatal, 262
HIV vaccines
partially effective, impact of on intravenous drug users, 132
safety and immunogenicity of with *rgp*120, 254
Hodgkin disease, in HIV-positive individuals in India, 181
Homosexual transmission, of HIV in STD clinic patients, 478
Hormonal contraception, male viral load and heterosexual transmission of HIV-1 subtype E with, 275
Hospital outpatients, HIV-1 and HIV-2 seroprevalence and risk factors among, 511
Hotel workers, HIV-1 epidemic among in Tanzania, 409
HTLV-I/II, gene sequences of in myasthenia gravis, 300
HTLV-I/II *tax-rex* genes, in myasthenia gravis patients, 300
Human herpesvirus 8 (HHV-8) seroprevalence, in HIV-infected patients, 295
Human leukocyte antigen typing, HIV source partner identification and, 232
Hydroxyurea, added to stavudine plus didanosine and nevirapine regimen, toxicity with no increased efficacy of, 368
Hypofibrinolytic state, with protease inhibitor-containing HAART, 441

Immune activation, cyclosporin-A in, 356
Immune function, with interleukin-2 for HIV/hepatitis C virus coinfection, 145
Immune modulator, viral load and, 221
Immune reconstitution
after HAART, 429
after protease inhibitor-based and -sparing regimens (letter), 544
with once-daily saquinavir soft-gelatin capsules/ritonavir therapy, 464

Immune response, cellular, in HIV-infected patients with histoplasmosis, 49
Immunologic markers, predictive value of after HIV-1 infection, 346
Incarceration, HIV risk with, 86
India, lymphoid neoplasms in HIV-positive individuals in, 181
Indinavir
  pharmacokinetic variability to with gender (letter), 101
  sequencing of, S19
  trough concentration of, 374
Indinavir C_{min}, higher toxicity with, 374
Indinavir-ritonavir 800/100 mg, twice-daily regimen, 374
Infants, dose-escalating study of safety and pharmacokinetics of nelfinavir in, 455
Injection drug users
  female, prevalence of iron deficiency and anemia among, 142
  HIV-1/hepatitis C virus coinfection among, 191
  HIV-1 RNA viral load monitoring in, 270
  HIV-infected young men, in northern Thailand, 62
  HIV risk with incarceration of, 86
  impact of partially effective HIV vaccine on, 132
  selenium status and mycobacterial disease among, 169
  women, HAART for, 69
Insulin-like growth factor, fetal levels of after tenofovir administration in gravid Rhesus monkeys, 207
Insulin resistance
  with antiretroviral therapy, 32
  with protease inhibitor-containing HAART, 441
Interferon-γ, in cellular immune response with histoplasmosis, 49
Interleukin-2
  effect of on viral burden, 221
  sustained suppression of HCV replication and inflammatory activity with, 145
Intervention strategies, for adherence, S2
Iron deficiency, prevalence of in female injection drug users, 142
Italy
  declining tuberculosis and drug resistance rates with HAART in (letter), 546
  excess mortality from non-AIDS-related diseases among HIV-infected individuals in (letter), 105
Ivory Coast, clinical biological evolution of HIV-1 seroconverters in, 149

Kaposi sarcoma
  with HIV infection from 1987–1999, 378
  in people with AIDS in the United States, 418
  prevalence of in HIV-infected patients, 295
Kidney disease, with HIV infection from 1987–1999, 378

Laboratory reporting system, non-name-based, 504
Lactic acidemia, with long-term antiretroviral therapy, S28
Lactic acidosis, with long-term antiretroviral therapy, S28
Lamivudine, for *Erythrocebus patas* monkeys, 323
Lentivirus, in resistance to virulent FIV superinfection, 1
Leptin, in HIV-infected men treated with antiretroviral therapy, 32
Letters to editor
  declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy, 546
  evaluation of two rapid HIV screening tests for the detection of HIV-2 antibody, 320
  excess mortality from liver disease and other non-AIDS-related diseases among HIV-infected individuals in Italy, 105
  factors associated with the time elapsed between initial detection of HIV antibodies and first contact for healthcare in HIV seroconverters of the Lyon University Hospitals, 319
  genetic analysis of HIV-1 discordant couples in Thailand: association of CCR2 64I homozygosity with HIV-1-negative status, 314
  genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas, 317
  hepatitis C virus infection in long-term nonprogressor HIV-1-infected subjects, 204
  how many people are at risk for HIV in the United States? the need for behavioral surveys of at-risk populations, 104
  immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens, 544
  influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy, 315
  multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase *pol* gene, 102
  pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men?, 101
  safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting, 547
  thymic size and muscle mass of HIV-infected asymptomatic children from Burkina Faso, 427
  vitamin A deficiency and genital tract infections in women living in central Africa, 203
Lion lentivirus, in resistance to virulent FIV superinfection, 1
Lipid abnormalities, with hepatitis C virus coinfections (letter), 315
Lipoatrophy, with antiretroviral therapy, 32
Lipodystrophy
  with long-term antiretroviral therapy, S28
  nucleoside analog reverse transcriptase inhibitors associated, 117
  with protease inhibitor-containing HAART, 441
Lipodystrophy syndrome, with antiretroviral therapy, 32
Liver cirrhosis, with HIV/hepatitis C virus coinfection, 145
Liver disease
  excess mortality from in HIV-infected individuals in Italy (letter), 105
  with HIV infection from 1987–1999, 378
Long-term antiretroviral therapy
  navigating emerging challenges to, S1
  toxic effects of, S28
Long-term nonprogressors, hepatitis C virus in (letter), 204
Lymphoid neoplasms, in HIV-positive individuals in India, 181

Lymphoma
AIDS-related systemic non-Hodgkin, detection of SV40 tumor antigen in, 109
non-Hodgkin
in HIV-positive individuals in India, 181
impact of HAART on, 388
in people with AIDS in the United States, 418
pleural and peritoneal, in people with AIDS in the United States, 418
Lymphoproliferative response, in HIV-infected patients with histoplasmosis, 49

Male viral load, heterosexual HIV-1 subtype E transmission and in northern Thailand, 275
Malnutrition, among drug users on HAART, 169
Malondialdehyde, oxidative stress and in HIV infection, 158
Maternal HIV-1 antibody, in subtype C virus infection, 435
Maternal outcome, after tenofovir administration, 207
Mathematic models, for impact of partially effective HIV vaccine on intravenous drug users, 132
Medicaid, in HIV-1 RNA viral load monitoring in drug users, 270
Medical care, for HIV-infected women, 69
Metabolic disorders, with long-term therapy, S28
Metabolic syndrome, with protease inhibitor-containing HAART, 441
Metabolism, changes of in protease inhibitor-naive HIV-1-infected patients treated with nucleoside reverse transcriptase inhibitors, 21
Military, HIV-infected young men in Thailand, 62
Mitochondrial DNA, nucleoside analog reverse transcriptase inhibitor-associated defects in, 117
Molecular confirmation, HIV source partner identification and, 232
Molecular epidemiology, of HIV-1 in Argentina, 422
Monkeys
antiretroviral nucleoside analog therapy in, 323
fetal and maternal outcome after tenofovir administration in, 207
Mortality rates, from liver disease and other non-AIDS-related disease among HIV-infected individuals in Italy (letter), 105
Mother-to-child transmission
in HIV-1 subtype C virus, 435
risk factors for, 262
Motor deficits, HIV-1-associated, 363
Multidrug regimen, two-year outcome of, 58
Multidrug resistance, dioxolane guanosine and, 11
Multidrug-resistant HIV-1, RNA and proviral DNA variants harboring new dipeptide insertions in (letter), 102
Muscle mass, in HIV-infected asymptomatic children from Burkina Faso (letter), 427
Myasthenia gravis, genetic sequences in, 300
Mycobacterial disease, pathogenesis of and selenium status, 169
Mycobacterium avium complex infection, impact of HAART on, 388

Natural history, of HIV-1 seroconverters, 149
Needle/syringe sharing, HIV-1/hepatitis C virus coinfection and, 191
Nelfinavir, dose-escalating study of safety and pharmacokinetics of, 455
Neoplasms, lymphoid, in HIV-positive individuals in India, 181
Neutralizing antibodies, in HIV-1 subtype C virus, 435
Nevirapine
CNS effects of, 363
hydroxyurea added to stavudine plus didanosine and, 368
pharmacokinetic interactions with ethinyl estradiol/norethindrone, 471
Non-Hodgkin lymphoma, in HIV-positive individuals in India, 181
Nonnucleoside reverse transcriptase inhibitors
immune reconstitution 1 year after therapy with, 429
in inhibition of drug-resistant HIV-1 isolates, 11
lack of hepatotoxicity with, 340
monitoring resistance to in developing countries, 165
sequencing options for, S19
therapeutic effects of on central nervous system in HIV-1-infected patients, 363
Norethindrone, pharmacokinetic interactions with nevirapine, 471
Nucleoside analog reverse transcriptase inhibitors
genetic and structural defects of adipose tissue mitochondria associated with in HIV patients, 117
monitoring resistance to in developing countries, 165
Nucleoside analog therapy
in *Erythrocebus patas* monkeys, 323
toxicity with long-term therapy, S28
Nucleoside reverse transcriptase inhibitors
body habitus and metabolic changes with in protease inhibitor-naive HIV-1-infected patients, 21
in inhibition of drug-resistant HIV-1 isolates, 11
sequencing of, S19

Opportunistic infections, trends in from 1987–1999, 378
Oral contraceptives, pharmacokinetic interaction with nevirapine, 471
Organ transplantation, cyclosporin-A in, 356
Outcomes
gender and after HAART, 917
of multidrug regimen after protease inhibitor failure, 58
Outpatient care, for HIV-infected drug users, 270
Oxidative stress, antioxidant intake and in HIV infection, 158

P-glycoprotein, in protease inhibitor pharmacokinetics, S11
p53 protein, lymphoid neoplasms and in HIV-positive individuals in India, 181
Partner communication, HIV-1 incidence and in northern Thailand, 284
Pathogenesis, of FIV superinfection, 1
Patient beliefs, in adherence to antiretroviral regimen, S2
Pediatric AIDS, survival with, 396
Perinatal transmission
combination therapy strategies to prevent, 484
placental inflammation and, 262
Peritoneal lymphoma, in people with AIDS in the United States, 418

Pharmacokinetics
gender and (letter), 101
of nelfinavir in HIV-exposed neonates, 455
of nevirapine and ethinyl estradiol/norethindrone, 471
of protease inhibitors, S11
of saquinavir soft-gelatin capsules/ritonavir, 464
Placebo-controlled trial, of cyclosporin-A, 356
Placental inflammation, with perinatal HIV transmission, 262
Plasma drug concentrations, in protease inhibitor pharmacokinetics, S11
Plasma protein binding, in protease inhibitor pharmacokinetics, S11
Plasmacytoma, in HIV-positive individuals in India, 181
Plasminogen activator inhibitor type I, with protease inhibitor-containing HAART, 441
Pleural lymphoma, in people with AIDS in the United States, 418
Pneumocystis carinii pneumonia, impact of HAART on, 388
pol gene sequence, in myasthenia gravis patients, 300
Polymerase chain reaction analysis, for genetic sequences in myasthenia gravis, 300
Polyomavirus, detection of in AIDS-related systemic non-Hodgkin lymphoma, 109
Population-based study, of safety and tolerability of combination post-exposure prophylaxis (letter), 547
Pregnancy
combination therapy strategies during, 484
outcome of after tenofovir administration, 207
Prevalence trends, of HHV-8 in HIV-infected patients, 295
Prevention behaviors
among female bar and hotel workers in northern Tanzania, 409
clinic-based counseling on and HIV-1 incidence, 284
monitoring of among gay and bisexual men, 76
Primary effusion lymphoma, in people with AIDS in the United States, 418
Primates, nonhuman, antiretroviral nucleoside analog therapy in, 323
Prison population, HIV risk among injection drug users in, 86
Prognosis, immunologic and virologic markers in, 346
Prophylaxis, safety and tolerability of (letter), 547
Prostitutes, and HIV infection in young men in Thailand, 62
Protease inhibitor-based antiretroviral regimens
immune reconstitution after (letter), 544
quality of life, emotional status, and adherence with, 232
Protease inhibitor-sparing antiretroviral regimens, immune reconstitution after (letter), 544
Protease inhibitors
dose-escalating study of safety and pharmacokinetics of, 455
in female injection drug users with iron deficiency and anemia, 142
hepatotoxicity development during, 41
hypofibrinolytic state with, 441
immune reconstitution 1 year after therapy with, 429
monitoring resistance to in developing countries, 165
pharmacokinetic enhancement of, S11
sequencing options for, S19
simplifying with once-daily dosing, 464
two-year outcome of multidrug regimen after failure to respond to, 58
Proviral DNA variants, in multidrug-resistant HIV-1 (letter), 102
Pseudotype-like virion structure, identification of, 536
Psychiatric disorders, in adherence to antiretroviral regimen, S2
Puma lentivirus, in resistance to virulent FIV superinfection, 1

Quality of life
with HAART, 54
in HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens, 232

Recombinant HIV-1 virus, in west Africa, 522
Recombinant interleukin-2, effect of on viral burden, 221
Repeat HIV testing
among young gay and bisexual men, 76
predictors of, 76
Reporting systems, non-name-based, 504
Resistance, dioxolane guanosine and, 11
Retrovirus, lentiviruses in resistance to, 1
Reverse transcriptase inhibitors
genetic and structural defects of adipose tissue mitochondria associated with, 117
immune reconstitution 1 year after therapy with, 429
lack of hepatotoxicity with, 340
monitoring resistance to in developing countries, 165
sequencing options for, S19
therapeutic effects of on central nervous system in HIV-1-infected patients, 363
Reverse transcriptase *pol* gene, multidrug-resistant HIV-1 RNA and proviral DNA variants harboring dipeptide insertions in (letter), 102
Rhesus monkeys, fetal and maternal outcome after tenofovir administration in, 207
Risk behaviors
impact of partially effective HIV vaccine and, 132
repeat HIV testing and among gay and bisexual men, 76
self-reported, decreasing with increased HIV incidence, 289
Risk factors
among female bar and hotel workers in northern Tanzania, 409
HIV-1 and HIV-2 seroprevalence and, 511
Ritonavir, simplified once-daily therapy of, 464
RNA variants, in multidrug-resistant HIV-1 (letter), 102
rpg120, with high-titered canarypox vaccines, safety and immunogenicity of, 254
Rural populations, independent effects of sexually transmitted disease and sexual behavior on HIV-1 prevalence in, 174

Safety
of combination antiretroviral post-exposure prophylaxis (letter), 547
of nelfinavir in HIV-exposed neonates, 455
San Francisco, non-name-based HIV reporting system in, 504
Saquinavir, simplified once-daily therapy of, 464

Selenium
impact of on mycobacterial disease pathogenesis in HIV-1 infected drug users during era of HAART, 169
oxidative stress and in HIV infection, 158
Semiurban community, HIV infection in, 402
Sequence analysis, for genetic sequences in myasthenia gravis, 300
Sequencing, antiretroviral, S19
Seroconversion, syncytium-inducing virus acquired at, 307
Seroprevalence, risk factors and among hospital outpatients in West Africa, 511
Sex workers, HIV exposure risk among, 517
Sexual behaviors
among gay and bisexual men using crack cocaine, 95
independent effects of on HIV-1 prevalence in rural Uganda, 174
and use of sexually transmitted disease clinic, 289
Sexual transmission, HIV source partner identification and molecular confirmation of, 232
Sexually transmitted disease
HIV seroincidence with, 478
independent effects of on HIV-1 prevalence in rural Uganda, 174
in male viral load and heterosexual transmission of HIV-1 subtype E, 275
risk of among commercial sex workers in Burkina Faso, 517
Sexually transmitted disease (STD) clinics
HIV seroincidence in patients at, 478
use of by known HIV-positive adults, 289
Simian immunodeficiency virus, tenofovir crossing placenta with treatment for during pregnancy, 207
Simian virus 40 tumor antigen DNA, detection of in AIDS-related systemic non-Hodgkin lymphoma, 109
Sociodemographic factors, in adherence to antiretroviral regimen, S2
Socioeconomic status, crack/cocaine use and with unprotected anal sex in gay and bisexual men, 95
Solid organ transplantation, cyclosporin-A placebo-controlled trial of, 356
South Africa, high incidence of HIV-1 in, 531
South America, HIV-1 epidemics in, 422
Spain, identifying HIV-1 BG intersubtype circulating recombinant form in, 536
Specialist care, for HIV-infected women, 69
Stavudine plus didanosine and nevirapine regimen, hydroxyurea added to, 368
Substance abuse, HIV-1 RNA viral load monitoring with, 270
Superinfection, by FIV, lion and puma lentiviruses in resistance to, 1
Surveillance
of HIV-1 genetic subtypes distribution and spread, 184
non-name-based reporting systems in, 504
Survival rates, gender and after HAART, 917
Syncytium-inducing virus, acquisition of at seroconversion, 307

T-cells
function of after HAART, 429
subsets of, 429
Tanzania, HIV-1 epidemic among female bar and hotel workers in, 409
tax genes, in myasthenia gravis patients, 300
3TC-DNA incorporation, in antiretroviral nucleoside analog therapy, 323
Teenagers, independent effects of sexually transmitted disease and sexual behavior on HIV-1 prevalence among, 174
Tenofovir, fetal and maternal outcome after administration of in gravid Rhesus monkeys, 207
Texas, genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in (letter), 317
Thailand
clinic-based counseling on preventive behaviors and HIV-1 incidence among married women in, 284
genetic analysis of HIV-1 discordant couples in (letter), 314
HIV infection in young men in, 62
impact of partially effective HIV vaccine on intravenous drug users in, 132
incarceration and HIV risk among injection drug users in, 86
male viral load and heterosexual transmission of HIV-1 subtype E in, 275
Therapeutic drug monitoring, of protease inhibitors, S11
Therapy switching, prevalence of in women's interagency HIV study, 495
Thymus gland, in HIV-infected asymptomatic children from Burkina Faso (letter), 427
Tolerance, of combination antiretroviral post-exposure prophylaxis (letter), 547
Total body bone mineral content (TBBMC), in prepubertal HIV-infected children, 450
Toxicity
high indinavir C_{min} with, 374
with hydroxyurea added to stavudine plus didanosine and nevirapine regimen, 368
Transplacental genotoxicity, of combined antiretroviral nucleoside analog therapy in *Erythrocebus patas* monkeys, 323
Tuberculosis
among drug users on HAART, 169
declining rates of among HIV-positive patients in Italian teaching hospital (letter), 546
impact of HAART on, 388
Tumor antigen *(T-ag)*, detection of in AIDS-related systemic non-Hodgkin lymphoma, 109

Uganda, independent effects of sexually transmitted disease and sexual behavior on HIV-1 prevalence in, 174
United States, need for behavioral surveys of at-risk populations in (letter), 104

Vaccine preparedness studies, among gay and bisexual men using crack cocaine, 95
Vaccines
partially effective, impact of on intravenous drug users in Thailand, 132
safety and immunogenicity of with *rgp*120, 254
Vertical transmission
children and adolescents surviving with, 396
in subtype C virus infection, 435

Viral load
comparative analysis of on subtype quantification, 330
determination of, HIV source partner identification in, 232
in HIV-1 subtype E infected males in northern Thailand, 275
monitoring of in HIV-infected drug users on antiretroviral therapy, 270
with multidrug regimen, 58
with recombinant interleukin-2, 221
with simplified once-daily therapy of saquinavir/ritonavir, 464
Virologic markers, predictive value of after HIV-1 infection, 346
Vitamin A deficiency, genital tract infections and in African women (letter), 203

West Africa, HIV infection in a semiurban community of, 402
Women
clinic-based counseling on preventive behaviors and HIV-1 incidence among, 284
HIV-1 epidemic among in bar and hotel workers in Tanzania, 409
HIV-infected, HAART therapy in, 69
independent effects of sexually transmitted disease and sexual behavior on HIV-1 prevalence among, 174
iron deficiency and anemia among injection drug using, 142
nevirapine interaction with oral contraceptives in, 471
pharmacokinetic variability to indinavir exposure in (letter), 101
prevalence and correlates of HAART switching in, 495
vitamin A deficiency and genital tract infections among (letter), 203

ZDV-DNA incorporation, in antiretroviral nucleoside analog therapy, 323
Zidovudine, for *Erythrocebus patas* monkeys, 323